Telix Pharmaceuticals Completes Patient Enrollment in Phase Three Study of PSMA-PET Imaging Agents for Prostate Cancer Imaging

MT Newswires Live

昨天

Telix Pharmaceuticals (ASX:TLX) completed patient enrollment in the phase three BiPASS study of its prostate-specific membrane antigen positron emission tomography (PSMA-PET) imaging agents Gozellix and Illuccix for prostate cancer imaging in the pre-biopsy setting, with 350 patients enrolled in the US and Australia, according to a Wednesday Australian bourse filing.

The study seeks to evaluate whether the combination of magnetic resonance imaging and the imaging of prostate-specific membrane antigen with positron emission tomography/computed tomography with Telix's proprietary gallium-68-PSMA-PET agents can improve diagnostic accuracy, reduce unnecessary biopsies, or improve targeting of biopsy compared with current standard practice.

The firm also aligned with the US Food and Drug Administration on a new drug application pathway for BiPASS.

Its shares rose nearly 1% in recent trading on Wednesday.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/2664867645"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2664867645\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2664867645?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-02 08:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2664867645","market":"sg","top_or_hot":-1,"title":"Telix Pharmaceuticals Completes Patient Enrollment in Phase Three Study of PSMA-PET Imaging Agents for Prostate Cancer Imaging","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/TLX.AU\">Telix Pharmaceuticals</a> (ASX:TLX) completed patient enrollment in the phase three BiPASS study of its prostate-specific membrane antigen positron emission tomography (PSMA-PET) imaging agents Gozellix and Illuccix for prostate cancer imaging in the pre-biopsy setting, with 350 patients enrolled in the US and Australia, according to a Wednesday Australian bourse filing.</p><p>The study seeks to evaluate whether the combination of magnetic resonance imaging and the imaging of prostate-specific membrane antigen with positron emission tomography/computed tomography with Telix's proprietary gallium-68-PSMA-PET agents can improve diagnostic accuracy, reduce unnecessary biopsies, or improve targeting of biopsy compared with current standard practice.</p><p>The firm also aligned with the US Food and Drug Administration on a new drug application pathway for BiPASS.</p><p>Its shares rose nearly 1% in recent trading on Wednesday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Telix Pharmaceuticals Completes Patient Enrollment in Phase Three Study of PSMA-PET Imaging Agents for Prostate Cancer Imaging</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTelix Pharmaceuticals Completes Patient Enrollment in Phase Three Study of PSMA-PET Imaging Agents for Prostate Cancer Imaging\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-09-02 08:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/TLX.AU\">Telix Pharmaceuticals</a> (ASX:TLX) completed patient enrollment in the phase three BiPASS study of its prostate-specific membrane antigen positron emission tomography (PSMA-PET) imaging agents Gozellix and Illuccix for prostate cancer imaging in the pre-biopsy setting, with 350 patients enrolled in the US and Australia, according to a Wednesday Australian bourse filing.</p><p>The study seeks to evaluate whether the combination of magnetic resonance imaging and the imaging of prostate-specific membrane antigen with positron emission tomography/computed tomography with Telix's proprietary gallium-68-PSMA-PET agents can improve diagnostic accuracy, reduce unnecessary biopsies, or improve targeting of biopsy compared with current standard practice.</p><p>The firm also aligned with the US Food and Drug Administration on a new drug application pathway for BiPASS.</p><p>Its shares rose nearly 1% in recent trading on Wednesday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2664867645","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2664867645","pubTimestamp":1788310213,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Telix Pharmaceuticals (ASX:TLX) completed patient enrollment in the phase three BiPASS study of its prostate-specific membrane antigen positron emission tomography (PSMA-PET) imaging agents Gozellix a","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BK7067":"生物科技","TLX":"Telix Pharmaceuticals Ltd. (Uplisting)","TLX.AU":"TELIX PHARMACEUTICALS LTD"},"translate_title":"Telix Pharmaceuticals 完成用于前列腺癌成像的 PSMA-PET 显像剂三期研究的患者入组","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TLX":1.5,"TLX.AU":1},"content_text":"Telix Pharmaceuticals (ASX:TLX) completed patient enrollment in the phase three BiPASS study of its prostate-specific membrane antigen positron emission tomography (PSMA-PET) imaging agents Gozellix and Illuccix for prostate cancer imaging in the pre-biopsy setting, with 350 patients enrolled in the US and Australia, according to a Wednesday Australian bourse filing.The study seeks to evaluate whether the combination of magnetic resonance imaging and the imaging of prostate-specific membrane antigen with positron emission tomography/computed tomography with Telix's proprietary gallium-68-PSMA-PET agents can improve diagnostic accuracy, reduce unnecessary biopsies, or improve targeting of biopsy compared with current standard practice.The firm also aligned with the US Food and Drug Administration on a new drug application pathway for BiPASS.Its shares rose nearly 1% in recent trading on Wednesday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}